SCHEMBL877186

SCHEMBL877186

COc1ccc2c(c1)C1(NC(=O)NC1=O)C1COCCC1C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.39
PDE7A Q13946 2/20 0.39
AKR1B1 P15121 2/20 0.38
GRIN1 Q05586 4/20 0.38
GRIN2A Q12879 4/20 0.38
CYP3A4 P08684 2/20 0.38
SLC22A1 O15245 2/20 0.38
CYP2D6 P10635 2/20 0.38
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.37
THRB P10828 1/20 0.37
MAPK1 P28482 1/20 0.37
GRIN2D O15399 3/20 0.37
GRIN3B O60391 3/20 0.37
GRIN2B Q13224 3/20 0.37
GRIN2C Q14957 3/20 0.37
GRIN3A Q8TCU5 3/20 0.37
SLC6A4 P31645 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
ADRA2A P08913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892139 0.83 BACE1 (0.39) GRIN1GRIN2ACYP3A4SLC22A1CYP2D6
SCHEMBL877634 0.81 BACE1 (0.44) GRIN1GRIN2ASLC22A1CYP2D6TSHR
SCHEMBL877633 0.75 BACE1 (0.32)
SCHEMBL882561 0.71 BACE1 (0.64)
SCHEMBL891952 0.71 BACE1 (0.64)
SCHEMBL892304 0.68 ACHE (0.55) SIGMAR1HTR2AHTR2B
SCHEMBL878160 0.68 ACHE (0.55) SIGMAR1HTR2AHTR2B
SCHEMBL21360864 0.64 OPRM1 (0.47) GRIN1GRIN2ACYP3A4SLC22A1CYP2D6
SCHEMBL23396468 0.63 GRIN1 (0.67) GRIN1GRIN2ACYP3A4SLC22A1CYP2D6
SCHEMBL892115 0.63 BACE1 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-04-05 US disclosed
WO-2012040641-A2 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 TNF 4120/4885PDE7A 984/4885AKR1B1 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.